Skip to main content
. 2025 Jul 1;15:21521. doi: 10.1038/s41598-025-05780-w

Fig. 6.

Fig. 6

Application of the validated method in determination of PPIX levels in patient samples. Pharmacokinetic profiles of three patients enrolled in an ongoing SDT trial in plasma (A) and whole blood (B). Blood samples were taken at various time points after administration of a 10 mg/kg IV dose of 5-ALA. (C) Mean and individual levels of PPIX in patient plasma, whole blood, brain tumor (NET and ET regions shown) from 4 patients enrolled in clinical trial with identifier NCT05182905. Samples were obtained between 5–8 h after oral administration of 5-ALA (Gleolan, 20 mg/kg). (D) Individual levels of PPIX in patient intraoperative plasma and whole blood are correlated with their intraoperative brain tumor (ET) region as described in (C).